Thanks for that.
Do you think that SB, if taken up by the market because it happens to be a lot more effective than Qbrexza (or anything else), would in that case they need to up the co-pay and/or heavily discount the product? As opposed to Qbrexza who it seems are heavily discounting to try and retain some customer base because their product isn't all that good.
Bot Chart, page-7365
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
-0.005(1.47%) |
Mkt cap ! $608.8M | |||
| Open | High | Low | Value | Volume |
| 33.5¢ | 34.3¢ | 32.5¢ | $1.200M | 3.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 349093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 25403 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |